1.32
price up icon3.94%   0.05
 
loading
Schlusskurs vom Vortag:
$1.27
Offen:
$1.26
24-Stunden-Volumen:
227.24K
Relative Volume:
0.13
Marktkapitalisierung:
$456.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-1.6098
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
-8.97%
1M Leistung:
-5.71%
6M Leistung:
-47.41%
1J Leistung:
-45.90%
1-Tages-Spanne:
Value
$1.235
$1.33
1-Wochen-Bereich:
Value
$1.21
$1.4499
52-Wochen-Spanne:
Value
$1.01
$3.45

Erasca Inc Stock (ERAS) Company Profile

Name
Firmenname
Erasca Inc
Name
Telefon
(858) 465-6511
Name
Adresse
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Name
Mitarbeiter
129
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ERAS's Discussions on Twitter

Vergleichen Sie ERAS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ERAS
Erasca Inc
1.32 456.09M 0 -125.04M -122.99M -0.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.75 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.09 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.57 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.67 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.00 28.51B 3.81B -644.79M -669.77M -6.24

Erasca Inc Stock (ERAS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-26 Eingeleitet Raymond James Outperform
2024-11-18 Eingeleitet Jefferies Buy
2024-03-11 Eingeleitet CapitalOne Overweight
2024-01-05 Herabstufung BofA Securities Buy → Neutral
2023-10-11 Eingeleitet H.C. Wainwright Buy
2023-03-30 Eingeleitet Mizuho Buy
2023-02-24 Eingeleitet Goldman Buy
2023-02-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
Alle ansehen

Erasca Inc Aktie (ERAS) Neueste Nachrichten

pulisher
Jun 17, 2025

ERAS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com

Jun 17, 2025
pulisher
Jun 16, 2025

Ratio Analysis: Unpacking Northann Corp (NCL)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

Jun 16, 2025
pulisher
Jun 15, 2025

Erasca, Inc. (NASDAQ:ERAS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Bought by California State Teachers Retirement System - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.12 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Squarepoint Ops LLC Takes Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Cuts Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Purchased by Ameriprise Financial Inc. - Defense World

Jun 07, 2025
pulisher
Jun 04, 2025

Nuveen Asset Management LLC Acquires 72,121 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Erasca’s pan-KRAS inhibitor ERAS-4001 gains IND clearance - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Makes New Investment in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

FDA clears Erasca’s new cancer drug applications By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

FDA clears Erasca’s new cancer drug applications - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Erasca, Inc. Announces Ind Clearance for Potential First-In-Class and Best-In-Class Pan-Kras Inhibitor Eras-4001 - MarketScreener

Jun 02, 2025
pulisher
Jun 02, 2025

Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough: FDA Greenlights Novel Pan-KRAS Cancer Drug Targeting 2.2M Patients Worldwide - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Raises Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Deutsche Bank AG Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Jun 01, 2025
pulisher
May 30, 2025

Discover May 2025's Top Penny Stocks - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 29, 2025
pulisher
May 29, 2025

Precision Oncology Pioneer Erasca Sets Major Investor Presentations at Jefferies and Goldman Sachs Conferences - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLC - Defense World

May 26, 2025
pulisher
May 24, 2025

D. E. Shaw & Co. Inc. Has $927,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 24, 2025
pulisher
May 22, 2025

Northern Trust Corp Boosts Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 22, 2025
pulisher
May 21, 2025

Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of “Buy” by Analysts - Defense World

May 21, 2025
pulisher
May 20, 2025

Erasca Inc (NASDAQ: ERAS) Could Pass $5 In One Year Stock Forecast - Stocksregister

May 20, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Buys 10,899 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 18, 2025
pulisher
May 17, 2025

HC Wainwright Has Positive Forecast for Erasca Q2 Earnings - Defense World

May 17, 2025
pulisher
May 14, 2025

Erasca (ERAS) Target Price Adjusted by Guggenheim Analyst | ERAS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA clears Erasca’s new cancer drug ERAS-0015 By Investing.com - Investing.com India

May 14, 2025
pulisher
May 13, 2025

Erasca (ERAS) Advances RAS-Targeting Therapies with New Clinical Developments | ERAS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Erasca Reports First Quarter 2025 Business Updates and Financial Results - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Erasca Advances Two Novel Cancer Drugs to Clinic, Secures 3-Year Cash Runway with $411M - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Erasca Seeks Partner for Naporafenib to Extend Cash Runway - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | ERAS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

FDA clears Erasca’s new cancer drug ERAS-0015 - Investing.com

May 13, 2025
pulisher
May 13, 2025

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Dimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Purchases 10,458 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 13, 2025
pulisher
May 12, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Tower Research Capital LLC TRC - Defense World

May 12, 2025
pulisher
May 12, 2025

Erasca (ERAS) Expected to Announce Quarterly Earnings on Wednesday - Defense World

May 12, 2025
pulisher
May 08, 2025

MetLife Investment Management LLC Has $283,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 08, 2025
pulisher
May 07, 2025

Erasca to Present at the Bank of America Securities Health Care Conference - TradingView

May 07, 2025
pulisher
May 06, 2025

Recurrent Glioblastoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

May 06, 2025
pulisher
May 06, 2025

Invesco Ltd. Acquires 11,290 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 06, 2025
pulisher
May 06, 2025

Barclays PLC Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

May 06, 2025

Finanzdaten der Erasca Inc-Aktie (ERAS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.00
price up icon 1.52%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):